Using Idelalisib Instead of Chemotherapy to Treat CLL
Richard R. Furman, MD, a member of the Lymphoma/Myeloma Service in the Division of Hematology/Oncology at the New York Weill Cornell Medical Center, discusses the ability to avoid the administration of chemotherapy when using novel agents, such as idelalisib, to treat patients with chronic lymphocytic leukemia.
Richard R. Furman, MD, a member of the Lymphoma/Myeloma Service in the Division of Hematology/Oncology at the New York Weill Cornell Medical Center, discusses the ability to avoid the administration of chemotherapy when using novel agents, such as idelalisib, to treat patients with chronic lymphocytic leukemia.
Clinical Pearls:
- Using novel agents, such as idelalisib, instead of chemotherapy allows the patient to experience fewer serious adverse events
- Chemotherapy side effects include immunosuppression, myelosuppression, and the long-term risk of bone marrow failure and secondary cancers
- The avoidance of these side effects should prompt all physicians to consider avoiding chemotherapy treatment strategies whenever possible
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More
